Zoetis (NYSE:ZTS) Issues Quarterly Earnings Results

Zoetis (NYSE:ZTS) announced its quarterly earnings results on Thursday. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03, Zacks reports. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis updated its FY 2025 guidance to 6.000-6.100 EPS.

Zoetis Stock Performance

ZTS stock traded down $12.37 during midday trading on Thursday, hitting $161.51. The stock had a trading volume of 7,914,538 shares, compared to its average volume of 2,800,073. The firm has a market capitalization of $72.87 billion, a price-to-earnings ratio of 30.31, a P/E/G ratio of 2.77 and a beta of 0.90. Zoetis has a 52 week low of $144.80 and a 52 week high of $200.53. The stock has a 50-day simple moving average of $169.08 and a 200 day simple moving average of $179.08. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.24%. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Wall Street Analyst Weigh In

Several brokerages have commented on ZTS. Morgan Stanley lowered their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Piper Sandler reduced their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $214.00.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.